Meta-analytic review of the effect of subcutaneous sumatriptan in migraine headache

Donald L. Harrison, Marion K Slack

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To assess the size and consistency of the effects of sumatriptan 6 mg sc, compared with placebo, in the abortive treatment of migraine headaches across multiple studies using varied research designs and migraine diagnoses. Data Sources: English-language journal articles retrieved by a MEDLINE search of the years 1990-1994, International Pharmaceutical Abstracts, drug information personnel at Glaxo, Inc., and cited references of identified studies, as well as published reviews of sumatriptan; the search term was sumatriptan. Study Selection: All studies reporting results with sumatriptan 6 mg sc, compared with placebo, for the abortive treatment of migraine headaches were reviewed. The studies that were included varied with respect to research design used and migraine diagnosis. Data Extraction: Outcome measures included in this research were improvement at 60 and 120 minutes after administration, pain free at 60 and 120 minutes after administration, the need for a second dose, the need for rescue medication, and adverse effects. Individual study effect sizes were calculated for each outcome variable. Individual effect sizes were combined across all studies to determine the combined average effect size for each outcome measure. The effect size calculated for each outcome measure was both clinically and statistically significant. No statistically significant variations in the effects of sumatriptan, compared with placebo, on all outcome variables considered were detected. Conclusions: The effects of sumatriptan across studies are consistently large, clinically and statistically significant, and are independent of the research methods used (i.e., efficacy vs. effectiveness) and migraine diagnosis.

Original languageEnglish (US)
Pages (from-to)109-114
Number of pages6
JournalJournal of Pharmacy Technology
Volume12
Issue number3
StatePublished - May 1996

Fingerprint

Sumatriptan
Migraine Disorders
Placebos
Outcome Assessment (Health Care)
Research Design
Information Storage and Retrieval
Research
MEDLINE
Pharmaceutical Preparations
Language
Therapeutics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Meta-analytic review of the effect of subcutaneous sumatriptan in migraine headache. / Harrison, Donald L.; Slack, Marion K.

In: Journal of Pharmacy Technology, Vol. 12, No. 3, 05.1996, p. 109-114.

Research output: Contribution to journalArticle

@article{004899071dac49c7ad1cb5de1382970e,
title = "Meta-analytic review of the effect of subcutaneous sumatriptan in migraine headache",
abstract = "Objective: To assess the size and consistency of the effects of sumatriptan 6 mg sc, compared with placebo, in the abortive treatment of migraine headaches across multiple studies using varied research designs and migraine diagnoses. Data Sources: English-language journal articles retrieved by a MEDLINE search of the years 1990-1994, International Pharmaceutical Abstracts, drug information personnel at Glaxo, Inc., and cited references of identified studies, as well as published reviews of sumatriptan; the search term was sumatriptan. Study Selection: All studies reporting results with sumatriptan 6 mg sc, compared with placebo, for the abortive treatment of migraine headaches were reviewed. The studies that were included varied with respect to research design used and migraine diagnosis. Data Extraction: Outcome measures included in this research were improvement at 60 and 120 minutes after administration, pain free at 60 and 120 minutes after administration, the need for a second dose, the need for rescue medication, and adverse effects. Individual study effect sizes were calculated for each outcome variable. Individual effect sizes were combined across all studies to determine the combined average effect size for each outcome measure. The effect size calculated for each outcome measure was both clinically and statistically significant. No statistically significant variations in the effects of sumatriptan, compared with placebo, on all outcome variables considered were detected. Conclusions: The effects of sumatriptan across studies are consistently large, clinically and statistically significant, and are independent of the research methods used (i.e., efficacy vs. effectiveness) and migraine diagnosis.",
author = "Harrison, {Donald L.} and Slack, {Marion K}",
year = "1996",
month = "5",
language = "English (US)",
volume = "12",
pages = "109--114",
journal = "Journal of Pharmacy Technology",
issn = "8755-1225",
publisher = "Harvey Whitney Books Company",
number = "3",

}

TY - JOUR

T1 - Meta-analytic review of the effect of subcutaneous sumatriptan in migraine headache

AU - Harrison, Donald L.

AU - Slack, Marion K

PY - 1996/5

Y1 - 1996/5

N2 - Objective: To assess the size and consistency of the effects of sumatriptan 6 mg sc, compared with placebo, in the abortive treatment of migraine headaches across multiple studies using varied research designs and migraine diagnoses. Data Sources: English-language journal articles retrieved by a MEDLINE search of the years 1990-1994, International Pharmaceutical Abstracts, drug information personnel at Glaxo, Inc., and cited references of identified studies, as well as published reviews of sumatriptan; the search term was sumatriptan. Study Selection: All studies reporting results with sumatriptan 6 mg sc, compared with placebo, for the abortive treatment of migraine headaches were reviewed. The studies that were included varied with respect to research design used and migraine diagnosis. Data Extraction: Outcome measures included in this research were improvement at 60 and 120 minutes after administration, pain free at 60 and 120 minutes after administration, the need for a second dose, the need for rescue medication, and adverse effects. Individual study effect sizes were calculated for each outcome variable. Individual effect sizes were combined across all studies to determine the combined average effect size for each outcome measure. The effect size calculated for each outcome measure was both clinically and statistically significant. No statistically significant variations in the effects of sumatriptan, compared with placebo, on all outcome variables considered were detected. Conclusions: The effects of sumatriptan across studies are consistently large, clinically and statistically significant, and are independent of the research methods used (i.e., efficacy vs. effectiveness) and migraine diagnosis.

AB - Objective: To assess the size and consistency of the effects of sumatriptan 6 mg sc, compared with placebo, in the abortive treatment of migraine headaches across multiple studies using varied research designs and migraine diagnoses. Data Sources: English-language journal articles retrieved by a MEDLINE search of the years 1990-1994, International Pharmaceutical Abstracts, drug information personnel at Glaxo, Inc., and cited references of identified studies, as well as published reviews of sumatriptan; the search term was sumatriptan. Study Selection: All studies reporting results with sumatriptan 6 mg sc, compared with placebo, for the abortive treatment of migraine headaches were reviewed. The studies that were included varied with respect to research design used and migraine diagnosis. Data Extraction: Outcome measures included in this research were improvement at 60 and 120 minutes after administration, pain free at 60 and 120 minutes after administration, the need for a second dose, the need for rescue medication, and adverse effects. Individual study effect sizes were calculated for each outcome variable. Individual effect sizes were combined across all studies to determine the combined average effect size for each outcome measure. The effect size calculated for each outcome measure was both clinically and statistically significant. No statistically significant variations in the effects of sumatriptan, compared with placebo, on all outcome variables considered were detected. Conclusions: The effects of sumatriptan across studies are consistently large, clinically and statistically significant, and are independent of the research methods used (i.e., efficacy vs. effectiveness) and migraine diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=0029873699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029873699&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029873699

VL - 12

SP - 109

EP - 114

JO - Journal of Pharmacy Technology

JF - Journal of Pharmacy Technology

SN - 8755-1225

IS - 3

ER -